AVITA Medical (ASX:AVH) has reinforced the economic case for its RECELL System after new real-world data showed the technology can cut hospital stays for burn patients by more than a third, potentially unlocking significant savings for US healthcare providers.
The analysis, presented at the 2025 European Burn Association Congress in Berlin, drew on data from the US national burn registry and compared outcomes for 741 adults with deep partial-thickness burns. Patients treated with RECELL spent an average of 5.6 fewer days in hospital compared to those receiving split-thickness skin grafts, a 36 per cent reduction.
That shorter stay translates into financial impact. With the average US hospital bed costing US$7,554 per day, the study suggests RECELL could deliver more than US$42,000 in per-patient savings, excluding procedure and rehabilitation costs. Hospitals could also expand capacity, treating up to 13 additional patients per bed each year.
“These findings support the role of RECELL as a clinically validated, cost-effective option in modern burn management, and highlight the impact on patient outcomes, hospital efficiency, and resource utilisation,” said Dr Victoria Miles of Louisiana State University Health and Sciences Center, who presented the research.
The results come as burn care continues to strain hospital systems. According to the American Burn Association, US burn cases accounted for over 110,000 intensive care unit days in 2023, costing more than US$676 million. Technologies that can reduce hospital stays and free up capacity are drawing heightened attention from both clinicians and payers.
AVITA Chief Executive Jim Corbett said the data underscored the system-wide benefits of RECELL. “When you consider use of RECELL in deep partial-thickness burns requires 97.5 per cent less skin, with improved donor site healing, reduced pain and scarring, these insights reaffirm our commitment to delivering clinically meaningful solutions that benefit patients, providers, and the broader healthcare system,” he said.
For AVITA, the findings bolster its commercial case as it seeks to expand RECELL’s footprint in the US and abroad. The company is positioning the system not only as a breakthrough in regenerative medicine, but also as a way to drive efficiency in hospitals grappling with rising costs and limited capacity.
By linking clinical outcomes with quantifiable cost savings, AVITA is aiming to shift RECELL from a specialist tool into a standard of care in burn treatment, and in the process, capture a larger share of a multi-billion-dollar global wound care market.